Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1096509 | 0.99 | CASR (0.44) | CASRCYP2D6 | |
| SCHEMBL1105780 | 0.95 | CASR (0.42) | CASRCYP2D6 | |
| SCHEMBL1105782 | 0.95 | CASR (0.42) | CASRCYP2D6 | |
| SCHEMBL1105798 | 0.94 | CASR (0.41) | CASRCYP2D6 | |
| SCHEMBL1106019 | 0.93 | CASR (0.46) | CASRCYP2D6 | |
| SCHEMBL1105735 | 0.89 | CASR (0.42) | CASRCYP2D6 | |
| SCHEMBL13748654 | 0.88 | CASR (0.37) | CASR | |
| Hydrochloric Acid SCHEMBL1095001 | 0.88 | CASR (0.43) | CASRCYP2D6 | |
| SCHEMBL1105847 | 0.88 | CASR (0.46) | CASRCYP2D6 | |
| SCHEMBL1106022 | 0.88 | CASR (0.44) | CASRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | CASR 1/4885CYP2D6 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.